AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20805115
Drug: E5555 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E5555 (200 mg)
Trial: 11881864
Drug: β-adrenergic antagonists
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: β-adrenergic antagonists (β‐AAs)
Trial: 11881864
Drug: Acute administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute administration of β‐AAs
Trial: 9792124
Drug: Standard preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard preventive programme (control) comprising selective fissure sealing and application of topical fluorides
Trial: 6102940
Drug: Alprazolam (0.5‐3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (0.5‐3.0 mg)
Trial: 6102940
Drug: Diazepam (5‐60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (5‐60 mg)
Trial: 29061359
Drug: Root canal
RxNorm normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Root canal treatment
Trial: 25534724
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of LFF571 four times daily for 10 days
Trial: 23962593
Drug: Overall closed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall closed reduction treatment
Trial: 21258836
Drug: Goshajinkigan (GJG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goshajinkigan (GJG) 7.5 g/day during mFOLFOX6 therapy
Trial: 14985685
Drug: DHA group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA group (n=20) took active foods containing fish oil (3.6 g DHA/week) for 2 months
Trial: 9599737
Drug: Enuretic group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enuretic group (treatment)
Trial: 143889
Drug: Induced abortion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced abortion with concurrent tubal ligation (Group 1)
Trial: 9389847
Drug: Human albumin
RxNorm normalized name: Human albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human albumin priming solution
Trial: 3316303
Drug: Bendroflumethiazide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide (5 mg)
Trial: 3316303
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (Bendroflumethiazide + Nifedipine)
Trial: 31810865
Drug: Biomarker-guided recommendation
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biomarker-guided recommendation on antibiotics (n=104)
Trial: 31810865
Drug: Routine use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine use of antibiotics (n=106)
Trial: 18588355
Drug: NCB-02 (curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NCB-02 (curcumin 150 mg twice daily)
Trial: 14622893
Drug: Home-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based intervention consisting of 10 weekly lessons focusing on child health and home safety.
Trial: 8846863
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg twice daily)
Trial: 8846863
Drug: Tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (20 mg twice daily) after crossover
Trial: 1444318
Drug: MAB-T88 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAB-T88 (1 mg/kg)
Trial: 1444318
Drug: MAB-T88 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAB-T88 (4 mg/kg)
Trial: 1444318
Drug: MAB-T88 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAB-T88 (8 mg/kg)
Trial: 29901441
Drug: XIENCE (durable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XIENCE (durable polymer drug‐eluting stent)
Trial: 27082108
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg daily for a maximum of 12 weeks
Trial: 24158940
Drug: DA-6034 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-6034 10, 20, 50, 100 or 200 mg single dose
Trial: 24158940
Drug: DA-6034 40,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-6034 40, 100 or 200 mg/day multiple doses for 7 days
Trial: 24158940
Drug: Placebo (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (not specified dosage)
Trial: 16601828
Drug: 90 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 microg/kg rFVIIa (3 doses at 3-hour intervals)
Trial: 14585671
Drug: HA/Vi vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA/Vi vaccine
Trial: 14585671
Drug: Avaxim vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avaxim vaccine
Trial: 8624269
Drug: Pamidronate 120
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pamidronate 120 mg infusion
Trial: 6387529
Drug: Diazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (10 mg single dose and 30 mg/day for 2 weeks)
Trial: 6387529
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg single dose and 240 mg/day for 2 weeks)
Trial: 26273143
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose captopril (Cap1hr) before surgery with Iso (Cap1hr+Iso)
Trial: 26273143
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of captopril and Iso (Iso+Cap) in rabbits
Trial: 24151017
Drug: Sevelamer carbonate
RxNorm normalized name: Sevelamer Carbonate
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer carbonate (starting dose 800 mg three times daily)
Trial: 15037936
Drug: Micronized purified
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized purified flavonoid fraction with routine antibiotic and anti‐inflammatory treatment
Trial: 15037936
Drug: Routine antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine antibiotic and anti‐inflammatory treatment alone (control)
Trial: 11779396
Drug: Cold-adapted, live,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold-adapted, live, attenuated, trivalent, intranasal influenza vaccine (CAIV-T)
Trial: 7942878
Drug: Patient-controlled analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled analgesia (PCA) with morphine sulfate 1 mg or meperidine hydrochloride 10 mg, six-minute lockout period
Trial: 7942878
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) analgesic therapy with meperidine hydrochloride 75-100 mg every three to four hours as needed
Trial: 3392233
Drug: Nilvadipine 2
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine 2 mg
Trial: 3392233
Drug: Nilvadipine 6
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine 6 mg
Trial: 3392233
Drug: Nilvadipine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (all doses)
Trial: 31008870
Drug: 0.05 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 μg/kg/min norepinephrine
Trial: 31008870
Drug: 0.5 μg/kg/min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg/kg/min phenylephrine
Trial: 26980809
Drug: Subcutaneous 300
RxNorm normalized name: buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous 300 µg GCSF before implantation
Trial: 19112802
Drug: 2% mequinol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% mequinol (4‐hydroxyanisole, 4HA) and 0.01% tretinoin (Solagé) applied twice daily for 3 months
Trial: 8415169
Drug: Glass ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glass ionomer cement with daily application of sodium fluoride gel (pH 5.8)
Trial: 8415169
Drug: Glass ionomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glass ionomer cement without topical fluoride
Trial: 3535055
Drug: Oral norfloxacin
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral norfloxacin (400 mg every 12 hours)
Trial: 29367449
Drug: Zonisamide 50
RxNorm normalized name: zonisamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide 50 mg once daily
Trial: 17348239
Drug: Concurrent rhinoconjunctivitis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent rhinoconjunctivitis
Trial: 17348239
Drug: Concurrent chronic
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concurrent chronic flexural rash
Trial: 8865706
Drug: 3 l.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 l. min(‐1) oxygen with face mask for the initial 3 hours
Trial: 8865706
Drug: 3 l.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 l. min(‐1) oxygen inhalation through the face mask
Trial: 6435655
Drug: Ro 15‐1788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 15‐1788 (5 mg i.v.)
Trial: 31259655
Drug: FPS 100/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPS 100/50 μg once daily (QD)
Trial: 31259655
Drug: FPS 100/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPS 100/50 μg twice daily (BID)
Trial: 31259655
Drug: FPS 250/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPS 250/50 μg BID
Trial: 31259655
Drug: FPS 500/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPS 500/50 μg BID
Trial: 26977121
Drug: Standardised Fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised Fermented Papaya Gel (SFPG) applied intragingivally (7 g) for 15 minutes daily for 10 days
Trial: 26977121
Drug: Standardised Fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised Fermented Papaya Gel (SFPG)
Trial: 21186968
Drug: Psychotropic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotropic treatment history
Trial: 16936304
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill (OCP) [ethinyl estradiol (E(2)) 30 microg + desogestrel 150 microg]
Trial: 16936304
Drug: Norethisterone 10
RxNorm normalized name: ethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norethisterone 10 mg/day
Trial: 16936304
Drug: 17-betaE(2) 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-betaE(2) 4 mg/day
Trial: 11255520
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 14 days, followed by full‐dose (10 mg) ramipril until day 90
Trial: 11255520
Drug: Low‐dose (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐dose (0.625 mg) ramipril for 90 days
Trial: 11255520
Drug: Full‐dose ramipril
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full‐dose ramipril for 90 days
Trial: 28801421
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) group receiving 10 sessions of EA treatment over 4 weeks
Trial: 28801421
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care group not receiving EA treatment
Trial: 24122389
Drug: docetaxel/capecitabine (docetaxel:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel/capecitabine (docetaxel: 75 mg/m2 on day 1; capecitabine: 1,650 mg/m2 on days 1–14 every 3 weeks)
Trial: 24122389
Drug: docetaxel alone
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel alone (75 mg/m2 on day 1 every 3 weeks)
Trial: 24122389
Drug: pre-treatment Ki67LI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pre-treatment Ki67LI
Trial: 16823593
Drug: Chemotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy group treated with mitomycin C, 5‐fluorouracil (5‐FU), and HCFU
Trial: 16823593
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no postoperative adjuvant chemotherapy)
Trial: 12783913
Drug: 12.5 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg/d paroxetine CR
Trial: 12783913
Drug: 25.0 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25.0 mg/d paroxetine CR
Trial: 1299708
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg isoniazid (INH)
Trial: 24951609
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus chemotherapy (capecitabine or fluorouracil, plus cisplatin)
Trial: 16358878
Drug: Inosine pranobex
RxNorm normalized name: inosine pranobex
DrugBank: Inosine pranobex (DB13156)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inosine pranobex (Groprinosin) 50 mg/kg b.w/day for 10 days in 3 following months
Trial: 9856371
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (25 mmol/day or 1 g/day of calcium as calcium carbonate)
Trial: 2212020
Drug: Peripheral streptomycin/lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral streptomycin/lidocaine injections (S/L)
Trial: 38214
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg labetalol
Trial: 31549255
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (UC) with inhaled corticosteroids (ICS) alone or in combination with a long-acting β2-agonist (ICS/LABA)
Trial: 26130237
Drug: Ubiquinol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ubiquinol (200 mg enteral, twice a day for up to seven days)
Trial: 26130237
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice a day for up to seven days)
Trial: 11281339
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine GITS (90 mg/day)
Trial: 8201073
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy (flooding)
Trial: 3295317
Drug: 45% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45% BCAA intravenous solution
Trial: 3295317
Drug: 23% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23% BCAA intravenous solution
Trial: 28729154
Drug: Tremelimumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab (10 mg/kg) every 4 weeks for 7 doses and every 12 weeks thereafter until treatment discontinuation
Trial: 25987645
Drug: Clonazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonazepam (20 patients took 0.5 mg once a day for 2 weeks, then 0.5 mg in the morning and evening for the next 2 weeks)
Trial: 23372745
Drug: 3.36 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.36 g/d EPA and DHA
Trial: 21515479
Drug: Volume-controlled ventilation
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Volume-controlled ventilation (VCV) without positive end-expiratory pressure (PEEP) (VT=8 ml/kg, Rf=12/min)
Trial: 21515479
Drug: Small tidal
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small tidal volume ventilation with PEEP (VT=6 ml/kg, Rf=16/min, PEEP=5 cm H(2)O)
Trial: 19637348
Drug: Regimen A
RxNorm normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A (3-drug chemotherapy without ifosfamide)
Trial: 11570021
Drug: Sibutramine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (20 mg/d)
Trial: 7978471
Drug: Dichloroacetate (DCA)
RxNorm normalized name: dichloroacetate
DrugBank: Sodium dichloroacetate (DB16929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichloroacetate (DCA) 40 mg.kg‐1 infused over 60 min after induction of anesthesia and 4 h later
Trial: 2568015
Drug: Antacids in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids in very high doses
Trial: 2568015
Drug: Prokinetic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prokinetic drugs
Trial: 2568015
Drug: Antacids, antacid/alginate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids, antacid/alginate, metoclopramide, domperidone
Trial: 18340390
Drug: Home Blood
RxNorm normalized name: LifeSource Aneroid Home Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home Blood Pressure Monitoring (HBPM) with long-acting diltiazem (240 mg/day)
Trial: 17154747
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (IBCT and TBCT)
Trial: 31188778
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT), 9 individual sessions (weekly one session)
Trial: 24286408
Drug: NPPV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPPV treatment group (NPPV group)
Trial: 20924751
Drug: MDMA +
RxNorm normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA + THC (inhalation of 4, 6 and 6 mg, interval of 1.5 h)
Trial: 17567341
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.5% with 75 microg fentanyl (1.5 ml)
Trial: 17567341
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine 0.5% with 1.5 ml saline
Trial: 2913129
Drug: MC immunotherapy
RxNorm normalized name: MC-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC immunotherapy
Trial: 2913129
Drug: Placebo immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo immunotherapy
Trial: 31540867
Drug: Semaglutide 1·0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semaglutide 1·0 mg once weekly
Trial: 31540867
Drug: Canagliflozin 300
RxNorm normalized name: canagliflozin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 300 mg once daily
Trial: 29065390
Drug: Adapted treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted treatment
Trial: 23104320
Drug: Bupivacaine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (10 cc of 0.5% bupivacaine)
Trial: 23104320
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 cc of normal saline)
Trial: 21325108
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g ethanol/kg body mass; n = 15)
Trial: 21325108
Drug: Alcohol (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.8 g ethanol/kg body mass) during progressive LBNP
Trial: 19249634
Drug: Fampridine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fampridine (10 mg twice daily; n=229)
Trial: 16600233
Drug: Polymorphisms of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphisms of peroxisome proliferator-activated receptor-gamma (Pro12Ala)
Trial: 16600233
Drug: Polymorphisms of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphisms of peroxisome proliferator-activated receptor-coactivator-1 (Gly482Ser)
Trial: 16600233
Drug: Body mass
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Body mass index and reproductive hormones among various genotypic groups of PCOS
Trial: 6775561
Drug: Naloxone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (15 mg, intravenously)
Trial: 6775561
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution (equivalent volume to naloxone)
Trial: 6775561
Drug: Diazepam (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (15 mg, intravenously)
Trial: 24429275
Drug: RPL554 (0.009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPL554 (0.009 mg/kg)
Trial: 24429275
Drug: RPL554 (0.018
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPL554 (0.018 mg/kg)
Trial: 17284917
Drug: Brushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing with fluoride toothpaste or gel, and rinsing with a fluoride mouth rinse
Trial: 14754644
Drug: 1% coal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% coal tar lotion (Exorex)
Trial: 14754644
Drug: 5% conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% conventional coal tar lotion (Alphosyl)
Trial: 10322856
Drug: Yizhi capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yizhi capsule (YZC), 4 capsules each time, three times a day for two months
Trial: 10322856
Drug: Yizhi capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yizhi capsule (YZC)
Trial: 10322856
Drug: Hydergine, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydergine, 2 mg each time, three times a day for two months
Trial: 3449477
Drug: Postoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiation therapy (6,000 rad)
Trial: 3449477
Drug: Preoperative radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiation therapy (5,000 rad)